In diagnostic practice, immunohistochemical panels are currently used, including markers such as GFAP, OLIG2, ATRX, p53, Ki-67, and IDH1-R132H, which enable the differentiation of gliomas and a preliminary assessment of their malignancy [55,56]. This evidence concerns the gene OLIG2 and glioma.